Replies to post #140519 on Biotech Values

[genisi]

There should be a poster(s).

Phase 2 (Study 120) examining 12 weeks of treatment with GS-5885, GS-9451, tegobuvir (GS-9190) and ribavirin. Latebreaker Poster #1421:

http://mobile.ilcapp.eu/EASL_161/poster_24857/program.aspx